Tofacitinib is primarily reserved for patients who have not responded well to or cannot tolerate . Its approved uses include:

The FDA requires its most prominent "Boxed Warning" for tofacitinib due to increased risks of: (heart attack, stroke). Blood clots in the lungs, legs, or arteries. Certain cancers , particularly lymphoma and lung cancer.

(tuberculosis, fungal, or viral) that can lead to hospitalization or death. 🏥 Approved Uses

Tofacitinib Citrate (Xeljanz) | American College of Rheumatology

Tofacitinib citrate (brand name ) is a potent prescription medication in a class called Janus kinase (JAK) inhibitors . It is used to treat serious chronic inflammatory conditions by modulating the immune system. ⚠️ Critical Safety Warning (FDA Boxed Warning)